Clinical Trial

Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 10, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of pazopanib combined with TGI/CIV chemotherapy in children and adolescents with recurrent or refractory rhabdomyosarcoma.
Trial Details
NCT Number NCT06816771
Lead Sponsor Shandong Cancer Hospital and Institute
Conditions Rhabdomyosarcoma, Recurrent, Refractory
Enrollment 38 participants
Start Date 2025-02
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-10